Orphazyme ApS today announced the successful completion of a 20 million Euro Series B financing round. Kurma Partners and Idinvest Partners join the existing investor syndicate of Novo A/S, Sunstone Capital and Aescap Venture.

 Orphazyme ApS develops novel therapeutics for the treatment of rare and genetic diseases. The company was founded on pioneering research on the therapeutic potential of the cellular heat shock response and is now developing a family of well-tolerated small molecule inducers of heat shock proteins as treatments for lysosomal storage diseases and other neurodegenerative diseases. A clinical Phase 2 study in Niemann-Pick Disease type C, a detrimental lysosomal storage disease, is currently in preparation.